Annual Report - Merrill Lynch & Co., Inc. - Investor Relations

More documents

Recommendations

Info

[THIS PAGE INTENTIONALLY LEFT BLANK]
Page 1 and 2: POWERed for Growth 2010 Annual Repo
Page 4: To Our Employees and Shareholders:
Page 8: Our Priority Growth Initiatives are
Page 12: POWERed for Growth Boston Scientifi
Page 18: TABLE OF CONTENTS PART I ..........
Page 24: clinical organization to take full
Page 28: Intraluminal Ultrasound Imaging We
Page 32: Neurovascular In January 2011, we c
Page 36: Many components used in the manufac
Page 40: provide greater clarity to certain
Page 44: challenging the prices charged for
Page 48: organization; reimbursement practic
Page 52: ‰ Our ability to successfully ide
Page 56: levels or will not decline further,
Page 60: international markets are also bein
Page 64: isk of litigation, which could resu
Page 68: ‰ involve rigorous pre-clinical a
Page 72:
financial cost that does not exceed
Page 76:
adversely affect our ability to man
Page 80:
PART II ITEM 5. MARKET FOR REGISTRA
Page 84:
ITEM 6. SELECTED FINANCIAL DATA FIV
Page 88:
in millions, except per share data
Page 92:
maker system in these regions in th
Page 96:
Further, the price we pay for our s
Page 100:
ness and durability, which we launc
Page 104:
plan for changes to the 510(k) Subm
Page 108:
PART II The following table provide
Page 112:
Operating Expenses The following ta
Page 116:
Intangible Asset Impairment Charges
Page 120:
plan, and are recording a portion o
Page 124:
Restructuring and restructuring-rel
Page 128:
from a favorable taxpayer motion is
Page 132:
Financing Activities Our cash flows
Page 136:
could have a material adverse effec
Page 140:
eporting units, we assign goodwill
Page 144:
losses, including a rollforward of
Page 148:
this may be useful information to u
Page 152:
PART II Management’s Report on In
Page 156:
ITEM 7A. QUANTITATIVE AND QUALITATI
Page 160:
PART II ITEM 8. FINANCIAL STATEMENT
Page 164:
PART II CONSOLIDATED STATEMENTS OF
Page 168:
NOTE A—SIGNIFICANT ACCOUNTING POL
Page 172:
ecognized the associated revenue ov
Page 176:
We test our purchased research and
Page 180:
the investment. Further, evidence m
Page 184:
We use a December 31 measurement da
Page 188:
We accounted for these acquisitions
Page 192:
which was placed into escrow to be
Page 196:
exception of the U.S. CRM reporting
Page 200:
The 2009 and 2010 purchase price ad
Page 204:
Counterparty Credit Risk We do not
Page 208:
Assets and liabilities measured at
Page 212:
Term Loan and Revolving Credit Faci
Page 216:
counted $197 million of notes recei
Page 220:
PART II We recorded restructuring c
Page 224:
We made total cash payments associa
Page 228:
As of December 31, 2010, we have U.
Page 232:
and criminal proceedings, substanti
Page 236:
the remaining state law claims. On
Page 240:
on the motion was held on April 21,
Page 244:
costs for the devices. On December
Page 248:
stent product, when launched in the
Page 252:
On December 12, 2008, we submitted
Page 256:
The total intrinsic value of stock
Page 260:
NOTE P—SEGMENT REPORTING Each of
Page 264:
adopted Update No. 2010-20 for our
Page 268:
QUARTERLY RESULTS OF OPERATIONS (in
Page 272:
PART III ITEM 10. DIRECTORS, EXECUT
Page 276:
EXHIBIT NO. TITLE PART IV 4.14 Form
Page 280:
EXHIBIT NO. TITLE PART IV 10.25 Bos
Page 284:
EXHIBIT NO. TITLE PART IV 10.60 For
Page 288:
SIGNATURES Pursuant to the requirem
Page 292:
Schedule II VALUATION AND QUALIFYIN
Page 296:
EXHIBIT 12 BOSTON SCIENTIFIC CORPOR
Page 300:
EndoVascular Technologies, Inc. (De
Page 304:
CERTIFICATIONS I, J. Raymond Elliot
Page 308:
EXHIBIT 32.1 CERTIFICATION OF CHIEF
Page 312:
[THIS PAGE INTENTIONALLY LEFT BLANK
show all

Annual Report - Merrill Lynch & Co., Inc. - Investor Relations

Create successful ePaper yourself

Delete template?

Save as template?